Previous Close | 1.5300 |
Open | 1.5700 |
Bid | 1.3300 x 200 |
Ask | 2.1200 x 200 |
Day's Range | 1.5700 - 1.8372 |
52 Week Range | 1.4200 - 2.3600 |
Volume | |
Avg. Volume | 10,331 |
Market Cap | 22.399M |
Beta (5Y Monthly) | 0.17 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.4400 |
Earnings Date | May 07, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced that its product portfolio of FDA-approved brands delivered combined revenues of $8.5 million during the first quarter of 2024. The company ended the quarter with $82 million in total assets, $54 million in total liabilities and $27 million of shareholders' equity.
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2024 financial results and provide a company update after the market closes on Tuesday, May 7, 2024.
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced the release of a Special Report evaluating the growing amount of current data supporting the use of its Caldolor® product (intravenous ibuprofen, or IVIB) as a standard of care for the treatment of pain and fever in adults, children and infants.